See also this year's filing and all EDGAR filings for this company.
PDF Report 0001423824_2016_Alder_Biopharmaceuticals_INC.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'Regenerx Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'Keryx Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'Epirus Biopharmaceuticals Inc', 'shared_tokens': {'biopharmaceuticals'}}]} |
| warning | Missing logo | subcommand.report | {} |
Graph
Absolute values for 0001423824, Alder Biopharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 322,201,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 1,974,000 |
| 3 | remainder_Assets | 75,852,000 |
| 4 | LiabilitiesCurrent | 12,372,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 138,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 16,718,000 |
| 9 | ResearchAndDevelopmentExpense | 69,611,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 859,000 |
| 13 | remainder_ComprehensiveNetIncome | -479,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 400,027,000 |
| 1 | Liabilities | 12,510,000 |
| 2 | Expenses | 86,329,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 387,517,000 |
| 5 | NetIncome | -85,470,000 |
| 6 | ComprehensiveNetIncome | -85,709,500 |
| 7 | BaseVar | 250,102,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 3.68 |
| 9 | EconomicCapitalRatio | 4.16 |
Edgar->Model Mapping
Feature Distribution
Change over Time
